この記事の翻訳を準備しています。それまでの間、英語の原文を表示します。
ビジネス · 2013/6/41 分で読めます
Eli Lilly and Co.; Withdrawal of Approval of a New Drug Application for ORAFLEX
ローカル自動翻訳 · 情報源の原言語
概要
The Food and Drug Administration (FDA) is withdrawing approval of a new drug application (NDA) for ORAFLEX (benoxaprofen) Tablets, held by Eli Lilly and Co. (Lilly), Lilly Corporate Center, Indianapolis, IN 46285. Lilly has voluntarily requested that approval of this application be withdrawn, and has waived its opportunity for a hearing.
情報源の原言語: Federal Register — Food and Drug Administration原文の発表を開く →